When was Poseida Therapeutics founded?

Poseida Therapeutics was founded in 2015 and raised its 1st funding round within a year of its incorporation.

Where is Poseida Therapeutics located?

Poseida Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California.

How many employees does Poseida Therapeutics have?

As of Sep 30, 2026, the latest employee count at Poseida Therapeutics is 69.

Is Poseida Therapeutics a funded company?

Poseida Therapeutics is a funded company, having raised a total of $324M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 23, 2015.

How much is Poseida Therapeutics worth?

The last known valuation of Poseida Therapeutics was $***** as of Nov 26, 2024.

When was the latest funding round of Poseida Therapeutics?

Poseida Therapeutics' latest funding was a $***** Post IPO round on Aug 07, 2023, with participation from 1 investor.

Where does Poseida Therapeutics rank among its competitors?

Poseida Therapeutics ranks 44th amongst 682 active competitors, of which 259 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Poseida Therapeutics?

Poseida Therapeutics' top competitors include Senti Bio, Immuneel and TScan Therapeutics. Among them, Immuneel secured the most recent funding round in June, 2026.

Poseida Therapeutics - 2026 Company Profile, Funding, Competitors & Financials

Q: Is Poseida Therapeutics an acquired company?

Poseida Therapeutics got acquired by Roche on Nov 26, 2024.

Poseida Therapeutics is an acquired company based in San Diego (United States), founded in 2015. It operates as a Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies. Poseida Therapeutics has raised $324M in funding from investors like Fidelity Investments, Novartis and Longitude Capital, with last known valuation of $*****. The company has 682 active competitors, including 259 funded and 159 that have exited. Its top competitors include companies like Senti Bio, Immuneel and TScan Therapeutics.

Company Details

Developer of gene therapies for treating cancer and liver orphan disease by using gene-editing technologies. It is developing CAR-T and gene therapy products for cancer and orphan diseases. Poseida uses its genome engineering capabilities for effectively silencing target genes or inserting therapeutic genes. Proprietary tools include piggyBac DNA Modification System, CRISPR, TALEN, and Footprint-Free Gene Editing System, which are clean (synthetic and virus-free) and can be surgically precise.

Website: poseida.com
Social
Registered Address: San Diego, California

Key Metrics

Founded Year

2015

Location

San Diego, United States

Stage

Acquired

Total Funding

$324M in 6 rounds

Latest Funding Round

Post IPO, Aug 07, 2023, $*****

Last Known Valuation

$***** as on Nov 26, 2024

Investors

Fidelity Investments & 13 more

Ranked

44^th among 682 active competitors

Employee Count

69 as on Sep 30, 2026

Similar Companies

Senti Bio & 881 more

Exit Details

Acquired by Roche (Nov 26, 2024)

View Poseida Therapeutics' full profile

Poseida Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Poseida Therapeutics, Inc. CIN: 472846548 , United States, Active	Dec 31, 2014	-	348 (As on Dec 31, 2024)	-

Poseida Therapeutics got acquired by Roche on Nov 26, 2024 at an acquisition amount of $*****.

Click here to take a look at Poseida Therapeutics's acquisition in detail

Poseida Therapeutics has raised a total funding of $324M over 6 rounds. Its first funding round was on Dec 23, 2015. Its latest funding round was a Post IPO round on Aug 07, 2023 for $*****. 1 investor participated in its latest round. Poseida Therapeutics has 14 institutional investors.

Here is the list of recent funding rounds of Poseida Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 07, 2023	1183146	Post IPO	6353399	4743775	2864313	1114177
Jun 25, 2020	3026347	Series D	3147414	3328806	1960917	Rapha Capital Management & 2 more
Apr 22, 2019	3485825	Series C	6975454	2813258	Novartis	Aisling Capital & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of Poseida Therapeutics's funding rounds and investors

Poseida Therapeutics' employee count trend

Poseida Therapeutics has 69 employees as of Sep 26. Here is Poseida Therapeutics's employee count trend over the years:

Employee count trend for Poseida Therapeutics

Uncover Poseida Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Poseida Therapeutics include Senti Bio, Immuneel and TScan Therapeutics. Here is the list of Top 10 competitors of Poseida Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
2nd	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
3rd	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	RA Capital Management, Novartis & 9 others	70/100
4th	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	67/100
5th	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
6th	Immatics 2000, Tubingen (Germany), Public	Developer of T -cell-based immunotherapies for the treatment of cancer	$236M	Wellington Partners Venture Capital, Dievini ... & 18 others	67/100
7th	ImmunoACT 2018, Mumbai (India), Series B	Developer of cell and gene therapies for cancer treatment	$15.9M	SINE, Laurus Labs & 4 others	67/100
8th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	66/100
9th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Atlas Venture, Novartis & 10 others	66/100
10th	Cabaletta Bio 2017, Radnor (United States), Public	Developer of CAAR T cells for B cell-mediated autoimmune diseases	$88.3M	Boxer Capital, Redmile Group & 6 others	66/100
44th	Poseida Therapeutics 2015, San Diego (United States), Acquired	Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies	$324M	Boxer Capital, Perceptive Advisors & 12 others	50/100